Boston Scientific에 대한 매도 수량은 투자자에게 Boston Scientific의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Boston Scientific (NYSE:BSX) 주식, 공매도 수량 보고

Boston Scientific

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Analyst Color

Earnings

Equities

Large Cap

Mid Cap

Tech

ETFs

AMGN

AVGO

AZEK

DELL

Janus Henderson Group plc Ordinary Shares

KVYO

MNDY

NVDA

QGEN

SNOW

TOST

UPST

3분기 실적 시즌이 다가오면서, 골드만삭스는 투자자들이 재무 실적을 통해 수익을 올릴 수 있는 주요 주식 기회를 식별한 노트를 발표했다. 애널리스트 존 마샬(John Marshall)과 그의 팀은 목요일에 18개의 주식이 실적 상향 조정의 혜택을 받을 가능성이 있고, 7개의 주식은 하향 조정의 영향을 받을 가능성이 있다고 강조했다.

이번 실적 시즌에는 매수할 주식 18개, 매도할 주식 7개: 골드만삭스는 올해를 &#39;주식 선택자의 해&#39;

News

Previews

Trading Ideas

ABBV

AGYS

ASML

BJRI

CHKP

CHTR

CMCSA

DECK

GATX

GOOG

GOOGL

JNPR

NFLX

NXPI

ODFL

ORLY

SKYW

SPOT

TSLA

VRSN

S&amp;P 500 기업들 중 약 14%가 6월 분기 실적을 발표했으며, 더 넓은 지수를 구성하는 기업들의 혼합 실적 성장률은 여전히 ​​양호하다. 이번 주에는 기술 보고 시즌이 공식적으로 시작될 것이며, 이는 최근 주에 가파른 하락세를 보인 시장의 향방을 잠재적으로 결정할 수 있다.

테슬라, 알파벳, GM 및 포드가 이번 주 실적 발표 주도하며 상승세 유지 위해 고군분투

Boston Scientific Corporation Common Stock

Boston Scientific Corp

Basilisk - United States Dollar

BELO SUN MINING CORP ORD by Belo Sun Mining Corp.

Belo Sun Mining Corp

Analysts' ratings for Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) over the last quarter vary from bullish to bearish, as provided by 19 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">10</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Boston Scientific and provided 12-month price targets. The average target is $96.63, accompanied by a high estimate of $110.00 and a low estimate of $86.00. This current average reflects an increase of 8.57% from the previous average price target of $89.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1731960086_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of Boston Scientific's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$98.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$98.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$98.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$98.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Bob Hopkins</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$98.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$86.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$93.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$94.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$92.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$86.00</td>
<td>$78.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Boston Scientific. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Boston Scientific compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Boston Scientific's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Boston Scientific's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BSX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Boston Scientific analyst ratings.</a>
<h2>Unveiling the Story Behind Boston Scientific</h2>
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
<h3>Unraveling the Financial Story of Boston Scientific</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Boston Scientific's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 19.34%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Boston Scientific's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 11.14%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Boston Scientific's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.28%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Boston Scientific's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.25%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Boston Scientific's debt-to-equity ratio is below the industry average at 0.54, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Key Takeaways From Boston Scientific Analyst Ratings

On Saturday, Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) unveiled three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42024655/boston-scientific-watchman-flx-left-atrial-appendage-closure-device-demonstrates-superior-bleeding" rel="noreferrer noopener">Appendage Closure (LAAC) Device</a>.
The&nbsp;WATCHMAN implant device&nbsp;is about the size of a quarter and shaped like a parachute. It is <a target="_blank" href="https://www.beaumont.org/treatments/watchman#:~:text=The%20WATCHMAN%20implant%20device%20is,forming%20and%20causing%20a%20stroke." rel="noreferrer noopener">implanted</a> into the heart to close off the left atrial appendage, a blind pouch of heart tissue to prevent blood clots from forming and causing a stroke.
Key findings from the study comparing the device to first-line oral anticoagulation (OAC) – including direct oral anticoagulants (DOAC) (95%) and warfarin (5%) – for stroke risk reduction in patients with non-valvular atrial fibrillation following a cardiac ablation were presented at the American Heart Association&#8217;s Scientific Sessions 2024 and simultaneously <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2408308" target="_blank" rel="noreferrer noopener">published</a> in &#8220;The New England Journal of Medicine.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41634450/why-is-boston-scientific-stock-trading-lower-on-wednesday" rel="noreferrer noopener">Why is Boston Scientific Stock Trading Lower On Wednesday?</a>
The trial met the primary safety endpoint of non-procedural major bleeding or clinically relevant non-major bleeding at 36 months, with the WATCHMAN FLX device demonstrating superiority to OAC (8.5% vs.18.1%)
It also met the primary efficacy endpoint of all-cause death, stroke, or systemic embolism at 36 months, with the data showing non-inferiority of the device to OAC (5.4% vs. 5.8%).
Additional findings included non-inferiority of the WATCHMAN FLX device for the combined secondary endpoint of procedural and non-procedural major bleeding at 36 months (3.9% vs. 5.0%).
The OPTION trial included 1,600 patients.
In the trial, approximately 60% of device patients had their WATCHMAN FLX implant 90-180 days following their ablation procedure. The other nearly 40% of the device patients had the two procedures performed concomitantly, with the WATCHMAN FLX implant taking place after the ablation.
In addition to the OPTION trial, the WATCHMAN technology is being evaluated against DOAC as first-line therapy in lower-risk patients within the CHAMPION-AF randomized trial.
The latest-generation WATCHMAN FLX Pro LAAC Device was approved in the U.S. in 2023. It is similarly being studied in several clinical trials.
Price Action: BSX stock is up 4.36% at $90.79 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42038673/netflix-scores-big-beyonce-set-to-headline-nfl-christmas-halftime-show" target="_blank" rel="noreferrer noopener">Netflix Scores Big: Beyoncé Set To Headline NFL Christmas Halftime Show</a></li>
</ul>
Image: Shutterstock

Health Care

Movers

General

Why Is Medical Device Giant Boston Scientific Stock Trading Higher On Monday?

Needham analyst Mike Matson reiterates Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Hold.

Reiteration

Needham Reiterates Hold on Boston Scientific

WIIM

Boston Scientific shares are trading higher. The company announced on Saturday its WATCHMAN FLX device showed superior bleeding risk reduction.

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation

Reported Saturday, Boston Scientific's WATCHMAN FLX Device Shows Superior Bleeding Risk Reduction Compared To Oral Anticoagulants After Cardiac Ablation In OPTION Clinical Trial

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/22/24</td>
<td>$87.00</td>
<td>$27.8K</td>
<td>600</td>
<td>3.0K</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$70.00</td>
<td>$71.9K</td>
<td>2.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>ALT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$11.00</td>
<td>$41.8K</td>
<td>250</td>
<td>926</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$320.00</td>
<td>$376.7K</td>
<td>1.6K</td>
<td>760</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$65.00</td>
<td>$645.0K</td>
<td>1</td>
<td>750</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$55.00</td>
<td>$112.1K</td>
<td>1.7K</td>
<td>726</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$100.00</td>
<td>$59.3K</td>
<td>445</td>
<td>431</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$23.00</td>
<td>$95.7K</td>
<td>4.2K</td>
<td>288</td>
</tr>
<tr>
<td>PTGX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$35.00</td>
<td>$38.1K</td>
<td>48</td>
<td>268</td>
</tr>
<tr>
<td>INCY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$67.50</td>
<td>$35.5K</td>
<td>1.1K</td>
<td>157</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For BSX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), we notice a put option sweep that happens to be neutral, expiring in 9 day(s) on November 22, 2024. This event was a transfer of 316 contract(s) at a $87.00 strike. This particular put needed to be split into 38 different trades to become filled. The total cost received by the writing party (or parties) was $27.8K, with a price of $88.0 per contract. There were 600 open contracts at this strike prior to today, and today 3045 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a call option trade that happens to be bullish, expiring in 16 day(s) on November 29, 2024. This event was a transfer of 899 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $71.9K, with a price of $80.0 per contract. There were 2173 open contracts at this strike prior to today, and today 1039 contract(s) were bought and sold. 
• For ALT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), we notice a put option sweep that happens to be bullish, expiring in 2 day(s) on November 15, 2024. This event was a transfer of 416 contract(s) at a $11.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $41.8K, with a price of $100.0 per contract. There were 250 open contracts at this strike prior to today, and today 926 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a call option sweep with bearish sentiment. It expires in 37 day(s) on December 20, 2024. Parties traded 352 contract(s) at a $320.00 strike. This particular call needed to be split into 46 different trades to become filled. The total cost received by the writing party (or parties) was $376.7K, with a price of $1070.0 per contract. There were 1630 open contracts at this strike prior to today, and today 760 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a put option trade with bullish sentiment. It expires in 275 day(s) on August 15, 2025. Parties traded 750 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $645.0K, with a price of $860.0 per contract. There were 1 open contracts at this strike prior to today, and today 750 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a put option sweep with bullish sentiment. It expires in 219 day(s) on June 20, 2025. Parties traded 210 contract(s) at a $55.00 strike. This particular put needed to be split into 27 different trades to become filled. The total cost received by the writing party (or parties) was $112.1K, with a price of $533.0 per contract. There were 1798 open contracts at this strike prior to today, and today 726 contract(s) were bought and sold. 
• Regarding MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we observe a call option sweep with bullish sentiment. It expires in 219 day(s) on June 20, 2025. Parties traded 85 contract(s) at a $100.00 strike. This particular call needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $59.3K, with a price of $695.0 per contract. There were 445 open contracts at this strike prior to today, and today 431 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option sweep with bullish sentiment. It expires in 2 day(s) on November 15, 2024. Parties traded 174 contract(s) at a $23.00 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $95.7K, with a price of $549.0 per contract. There were 4250 open contracts at this strike prior to today, and today 288 contract(s) were bought and sold. 
• For PTGX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>), we notice a call option sweep that happens to be bearish, expiring in 65 day(s) on January 17, 2025. This event was a transfer of 37 contract(s) at a $35.00 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $38.1K, with a price of $1030.0 per contract. There were 48 open contracts at this strike prior to today, and today 268 contract(s) were bought and sold. 
• For INCY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), we notice a call option sweep that happens to be bullish, expiring in 2 day(s) on November 15, 2024. This event was a transfer of 25 contract(s) at a $67.50 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $35.5K, with a price of $1416.0 per contract. There were 1186 open contracts at this strike prior to today, and today 157 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

Hims & Hers Health, Inc. Class A Common Stock

HIMS

INCY

PTGX

VKTX

10 Health Care Stocks With Whale Alerts In Today's Session

Cortex is a privately held medical technology company focused on the development of a diagnostic mapping solution which may identify triggers and drivers outside of the pulmonary veins that are foundational to atrial fibrillation (AF), a heart rhythm disorder affecting nearly 38 million people globally.
&nbsp;
Boston Scientific expects to complete the transaction in the first half of 2025, subject to customary closing conditions. The transaction is expected to have an immaterial impact on adjusted earnings per share in 2025 and is expected to be slightly dilutive on a GAAP basis due to amortization expense and acquisition-related net charges.

Boston Scientific Has Agreed To Acquire Cortex, An Ajax Health Company, Specific Deal Terms Were Not Disclosed

On Wednesday,&nbsp;Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) released the results of the primary endpoint of the ACURATE IDE trial of&nbsp;ACURATE&nbsp;neo2 Aortic Valve System for patients with severe, symptomatic aortic stenosis at risk of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41629382/acurate-neo2-aortic-valve-system-data-presented-at-late-breaking-clinical-trial-session-at-tct-202" rel="noreferrer noopener">open-heart surgery</a>.
The data were presented at Transcatheter Cardiovascular Therapeutics 2024, the annual scientific symposium of the Cardiovascular Research Foundation.
This randomized trial evaluated the ACURATE&nbsp;neo2 valve, the company&#8217;s second-generation transcatheter aortic valve replacement (TAVR) technology, versus a pre-defined control valve, either the commercially available SAPIEN valve or the Evolut transcatheter aortic valve system.
SAPIEN valve is sold by Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), and Evolut is Medtronic Plc&#8217;s NYSE: MDT) brand.
The composite rate of all-cause mortality, stroke, or rehospitalization at one year was 16.16% in the ACURATE&nbsp;neo2 arm and 9.53% in the control arm, not meeting the prespecified criterion for non-inferiority (the posterior probability for non-inferiority was 77.9%, which is lower than the non-inferiority test threshold of 97.5%).
&#8220;This trial is the largest randomized comparison of TAVR platforms and was conducted over four years, including during a global pandemic that introduced complexities for enrollment,&#8221; said&nbsp;Michael Reardon, co-principal investigator of the ACURATE IDE trial.
The company also presented data from a post-hoc analysis to identify and evaluate expanded and under-expanded ACURATE&nbsp;neo2 valve frames within the ACURATE IDE trial.
The company reviewed key procedural factors, including pre-and post-dilation, which help prepare for, enable, and confirm proper valve expansion during the procedure.
Following this review, an assessment of implant quality for the ACURATE&nbsp;neo2 valve was initiated. The assessment highlighted that approximately 20% of the valves were under-expanded.
Data from the assessment also demonstrated that the rate of death, stroke, or rehospitalization at one year was similar between the ACURATE&nbsp;neo2 expanded group and the control group.
Boston Scientific continues to work closely with the U.S. Food and Drug Administration on the regulatory strategy for approval of the ACURATE valve platform in the U.S.
The ACURATE&nbsp;neo2 Aortic Valve System and the ACURATE Prime Aortic Valve System are approved in Europe.
In the&nbsp;U.S., the ACURATE&nbsp;neo2 Aortic Valve System and the ACURATE Prime Aortic Valve System are investigational devices.
Price Action: BSX stock is down 1.66% at $83.16 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41630458/cdw-shares-dip-as-q3-sales-miss-amid-weak-hardware-demand-and-customer-delays" target="_blank" rel="noreferrer noopener">CDW Shares Dip As Q3 Sales Miss Amid Weak Hardware Demand And Customer Delays</a></li>
</ul>

Why is Boston Scientific Stock Trading Lower On Wednesday?

Biotech

Boston Scientific's ACURATE neo2 Aortic Valve System Fails To Meet Non-Inferiority In Key Trial, Showing 16.16% Composite Rate Of Mortality, Stroke, Or Rehospitalization At One Year Versus 9.53% For Control Valve; Data Presented At TCT 2024

<a href="https://event.choruscall.com/mediaframe/webcast.html?webcastid=MY6v7nFk" title="https://event.choruscall.com/mediaframe/webcast.html?webcastid=MY6v7nFk">https://event.choruscall.com/mediaframe/webcast.html?webcastid=MY6v7nFk</a>

Shares Of Boston Scientific See Volume; Company To Provide Cardiology Business Update At 4:00 PM EDT

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) has outperformed the market over the past 15 years by 4.92% on an annualized basis producing an average annual return of 17.01%. Currently, Boston Scientific has a market capitalization of $125.17 billion. 
Buying $1000 In BSX: If an investor had bought $1000 of BSX stock 15 years ago, it would be worth $10,630.79 today based on a price of $85.00 for BSX at the time of writing.
<h3>Boston Scientific's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730215821_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth $11,000 Today

Bernstein analyst Lee Hambright maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Outperform and raises the price target from $92 to $100.

Price Target

Bernstein Maintains Outperform on Boston Scientific, Raises Price Target to $100

Morgan Stanley analyst Patrick Wood maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Overweight and raises the price target from $92 to $100.

Morgan Stanley Maintains Overweight on Boston Scientific, Raises Price Target to $100

RBC Capital analyst Shagun Singh maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Outperform and raises the price target from $95 to $98.

RBC Capital Maintains Outperform on Boston Scientific, Raises Price Target to $98

Wells Fargo analyst Larry Biegelsen maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Overweight and raises the price target from $87 to $98.

Wells Fargo Maintains Overweight on Boston Scientific, Raises Price Target to $98

Citigroup analyst Joanne Wuensch maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and raises the price target from $92 to $98.

Citigroup Maintains Buy on Boston Scientific, Raises Price Target to $98

Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and maintains $98 price target.

Canaccord Genuity Maintains Buy on Boston Scientific, Maintains $98 Price Target

Mizuho analyst Anthony Petrone maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Outperform and raises the price target from $100 to $110.

Mizuho Maintains Outperform on Boston Scientific, Raises Price Target to $110

Needham analyst Michael Matson maintained a Hold rating on Boston Scientific (BSX – Research Report) today. The company's shares closed last Friday...

Needham Keeps Their Hold Rating on Boston Scientific (BSX)

Boston Sci stock climbs 5% on positive Watchman FLX data

In a report released on November 15, David Rescott from Robert W. Baird maintained a Buy rating on Boston Scientific (BSX – Research Report), with ...

Buy Rating on Boston Scientific: WATCHMAN Product's Expanding Market Potential and Revenue Growth

Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on BSX stock, giving a Buy rating yesterday. Anthony Petrone has give...

Boston Scientific's WATCHMAN FLX: Poised for Growth with New Trial Results and Reimbursement Code

Fidelity Select Health Care Portfolio Q3 2024 Fund Review

Fidelity Balanced Fund Q3 2024 Review

JPMorgan's 'Analyst Focus List' – growth, income, value, short ideas

Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 17. Analyst Joanne Wue...

Boston Scientific's Growth Potential Boosted by Positive OPTION Trial Results and Regulatory Developments

Piper Sandler Releases a Buy Rating on Boston Scientific (BSX)

The latest announcement is out from Boston Scientific ( ($BSX) ). Boston Scientific Corporation has unveiled its 2025 Annual Bonus Plan and Perform...

Boston Scientific Launches 2025 Incentive Programs

AAPL

AGCO

ALNY

ALRM

AMAT

AMZN

ARGNF

ARGX

ARMK

ASND

BRBR

CVNA

CYBR

DAWN

DKNG

EWTX

EXAS

FBCG

FBCV

FBND

FBTC

FCLD

FCOM

FCOR

FCPI

FDHY

FDIG

FDIS

FDLO

FDMO

FDRR

FDVV

FENY

FETH

FHLC

FIDI

FIDU

FMAG

FMAT

FMET

FNCL

FQAL

FREL

FSMD

FSTA

FTEC

FUTY

FVAL

GWRE

INTC

ISRG

KLAC

KVUE

LEGN

LRCX

MSFT

NTRA

ONEQ

PCVX

PODD

QCOM

ROIV

RVMD

SCHW

SIRI

SNDX

SPGI

SWTX

TFII

TMUS

TRGP

TVTX

ULTA

VICI

XENE

Press Releases

Boston Scientific Receives Japanese Regulatory Approval for the FARAPULSE™ Pulsed Field Ablation System

Boston Scientific Announces Conference Call Discussing Third Quarter 2024 Results

Boston Scientific Launches Next Generation of Cardiac Mapping for the FARAPULSE™ Pulsed Field Ablation System

Boston Scientific Announces Results for Third Quarter 2024

ACURATE neo2™ Aortic Valve System Data Presented at Late-Breaking Clinical Trial Session at TCT 2024

Boston Scientific Announces Agreement to Acquire Cortex, Inc.

Comments

Boston Scientific

매도 수량

Boston Scientific (NYSE:BSX) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌